AMPH vs. NVO
Compare and contrast key facts about Amphastar Pharmaceuticals, Inc. (AMPH) and Novo Nordisk A/S (NVO).
Performance
AMPH vs. NVO - Performance Comparison
Loading graphics...
AMPH vs. NVO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
AMPH Amphastar Pharmaceuticals, Inc. | -26.85% | -27.88% | -39.97% | 120.74% | 20.31% | 15.81% | 4.25% | -3.07% | 3.43% | 4.45% |
NVO Novo Nordisk A/S | -25.12% | -39.22% | -15.93% | 54.84% | 22.66% | 63.52% | 23.33% | 28.70% | -12.98% | 52.92% |
Fundamentals
AMPH:
$923.94M
NVO:
$163.46B
AMPH:
$2.06
NVO:
$22.15
AMPH:
9.52
NVO:
1.66
AMPH:
0.50
NVO:
0.07
AMPH:
1.30
NVO:
0.55
AMPH:
1.17
NVO:
0.84
AMPH:
$719.89M
NVO:
$297.20B
AMPH:
$356.06M
NVO:
$240.66B
AMPH:
$191.74M
NVO:
$153.18B
Returns By Period
In the year-to-date period, AMPH achieves a -26.85% return, which is significantly lower than NVO's -25.12% return. Over the past 10 years, AMPH has underperformed NVO with an annualized return of 4.43%, while NVO has yielded a comparatively higher 5.13% annualized return.
AMPH
- 1D
- 1.93%
- 1M
- -3.16%
- YTD
- -26.85%
- 6M
- -26.49%
- 1Y
- -32.42%
- 3Y*
- -19.46%
- 5Y*
- 1.61%
- 10Y*
- 4.43%
NVO
- 1D
- 4.14%
- 1M
- 1.73%
- YTD
- -25.12%
- 6M
- -31.34%
- 1Y
- -44.52%
- 3Y*
- -20.64%
- 5Y*
- 3.88%
- 10Y*
- 5.13%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
AMPH vs. NVO — Risk / Return Rank
AMPH
NVO
AMPH vs. NVO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Amphastar Pharmaceuticals, Inc. (AMPH) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| AMPH | NVO | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.66 | -0.82 | +0.17 |
Sortino ratioReturn per unit of downside risk | -0.73 | -1.02 | +0.29 |
Omega ratioGain probability vs. loss probability | 0.90 | 0.86 | +0.04 |
Calmar ratioReturn relative to maximum drawdown | -0.76 | -0.79 | +0.03 |
Martin ratioReturn relative to average drawdown | -1.67 | -1.37 | -0.30 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| AMPH | NVO | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.66 | -0.82 | +0.17 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.04 | 0.10 | -0.07 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.11 | 0.16 | -0.05 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.17 | 0.46 | -0.29 |
Correlation
The correlation between AMPH and NVO is 0.24, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
AMPH vs. NVO - Dividend Comparison
AMPH has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 5.06%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AMPH Amphastar Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
NVO Novo Nordisk A/S | 5.06% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
Drawdowns
AMPH vs. NVO - Drawdown Comparison
The maximum AMPH drawdown since its inception was -72.04%, roughly equal to the maximum NVO drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for AMPH and NVO.
Loading graphics...
Drawdown Indicators
| AMPH | NVO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -72.04% | -74.70% | +2.66% |
Max Drawdown (1Y)Largest decline over 1 year | -41.01% | -55.03% | +14.02% |
Max Drawdown (5Y)Largest decline over 5 years | -72.04% | -74.70% | +2.66% |
Max Drawdown (10Y)Largest decline over 10 years | -72.04% | -74.70% | +2.66% |
Current DrawdownCurrent decline from peak | -69.86% | -73.25% | +3.39% |
Average DrawdownAverage peak-to-trough decline | -23.32% | -17.55% | -5.77% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 18.61% | 31.69% | -13.08% |
Volatility
AMPH vs. NVO - Volatility Comparison
Amphastar Pharmaceuticals, Inc. (AMPH) has a higher volatility of 12.83% compared to Novo Nordisk A/S (NVO) at 9.88%. This indicates that AMPH's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| AMPH | NVO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.83% | 9.88% | +2.95% |
Volatility (6M)Calculated over the trailing 6-month period | 38.92% | 38.79% | +0.13% |
Volatility (1Y)Calculated over the trailing 1-year period | 49.46% | 54.20% | -4.74% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 43.53% | 37.82% | +5.71% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 42.12% | 32.29% | +9.83% |
Financials
AMPH vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between Amphastar Pharmaceuticals, Inc. and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
AMPH vs. NVO - Profitability Comparison
AMPH - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Amphastar Pharmaceuticals, Inc. reported a gross profit of 85.67M and revenue of 183.11M. Therefore, the gross margin over that period was 46.8%.
NVO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Novo Nordisk A/S reported a gross profit of 54.38B and revenue of 67.28B. Therefore, the gross margin over that period was 80.8%.
AMPH - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Amphastar Pharmaceuticals, Inc. reported an operating income of 35.61M and revenue of 183.11M, resulting in an operating margin of 19.5%.
NVO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Novo Nordisk A/S reported an operating income of 27.12B and revenue of 67.28B, resulting in an operating margin of 40.3%.
AMPH - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Amphastar Pharmaceuticals, Inc. reported a net income of 24.43M and revenue of 183.11M, resulting in a net margin of 13.3%.
NVO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Novo Nordisk A/S reported a net income of 22.96B and revenue of 67.28B, resulting in a net margin of 34.1%.